Jason K. Garland net worth and biography

Jason Garland Biography and Net Worth

CFO of Repligen

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (“CFO”), where he oversees financial operations for the Company. In this position, he holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management, information technology and investor relations. Before joining Repligen, Mr. Garland was with Integer Holdings Corporation (“Integer”), a medical device outsource manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s business process excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at General Electric Corporation (“GE”). His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions, then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the board of directors at Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire and is Lean Six Sigma Black Belt certified.

What is Jason K. Garland's net worth?: The estimated net worth of Jason K. Garland is at least $2.65 million as of June 25th, 2026. Garland owns 19,359 shares of Repligen stock worth more than $2,649,666 as of June 30th. This net worth evaluation does not reflect any other assets that Garland may own. Learn More about Jason K. Garland's net worth.
How do I contact Jason K. Garland?: The corporate mailing address for Garland and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Jason K. Garland's contact information.
Has Jason K. Garland been buying or selling shares of Repligen?: During the last quarter, Jason K. Garland has sold $106,285.00 in Repligen stock. Most recently, Jason K. Garland sold 733 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a transaction totalling $106,285.00. Following the completion of the sale, the chief financial officer now directly owns 19,359 shares of the company's stock, valued at $2,807,055. Learn More on Jason K. Garland's trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Jason Garland (CFO), Jason Garland (CFO), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Margaret Pax (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 1 times. They purchased a total of 1,800 shares worth more than $201,834.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 50,390 shares worth more than $7,827,362.22. The most recent insider tranaction occured on June, 25th when CFO Jason K Garland sold 733 shares worth more than $106,285.00. Insiders at Repligen own 0.6% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 6/25/2026.

Jason K. Garland Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/25/2026	Sell	733	$145.00	$106,285.00	19,359

Jason K. Garland Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $136.65

$134.01

$138.85

50 Day Range

MA: $123.04

$102.87

$147.01

2 Week Range

Now: $136.65

$100.99

$175.77

Volume

365,448 shs

Average Volume

983,370 shs

Market Capitalization

$7.71 billion

P/E Ratio

151.70

Dividend Yield

N/A

Beta

1.09